# US 2004/0024015 A1 · Tumor radiosensitization and /or chemopotentiation using isocoumarin derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0024015 A1
- Document ID: US20040024015A1
- Status: Published application
- Kind: A1
- Application number: 10/610,022
- Filed: 2003-06-30
- Published: 2004-02-05
- Earliest claimed: 2000-02-29
- Inventors: Corinne L. Reimer; Naoki Agata; Tomio Takeuchi; Hiroyuki Kumagai; Takeo Yoshioka; Masaaki Ishizuka; Donald W. Kufe; Ralph R. Weichselbaum
- Web page: https://patentgrep.com/patent/US20040024015A1

## CPC

- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of cancer in animals, particularly humans, is provided wherein certain isocoumarin derivatives which exhibit unique radiosensitization activity and/or chemopotentiation properties are employed in a combination treatment with ionizing radiation and/or chemotherapy.

## Claims

### Claim 1

A method for inhibiting the growth of an endothelial cell comprising a contacting said endothelial cell with an isocoumarin derivative of the formula:
4
wherein each of X1, X2 and X3 is independently sulfur or oxygen; X4 is sulfur, oxygen or an —NH— group; R1 is hydrogen or C1-6 alkyl; and R2 and R3 may be the same or different and each represents C1-6 alkyl, and C7-10 alkaryl, hydroxy or hydrogen; and n is zero on a whole integer of 1 to 3; and
(b) further contacting said tumor cell with a chemotherapeutic agent,
wherein said dose of isocoumarin derivative, when combined with said dose chemotherapeutic agent is effective to inhibit the growth of said endothelial cell in an enhanced effect relative to administration of said isocoumarin derivative or said chemotherapeutic agent alone.

### Claim 2 (depends on 1, 2)

The method of claim 1,
wherein the isocoumarin derivative comprises a compound of the formula given in claim 1, wherein X1, X2 and X3 each are oxygen; X4 is oxygen or sulfur; R1 is C1-3 alkyl; R2 and R3 are each independently selected from hydrogen and C1-6 alkyl and n is 0, 1 or 2.
The method of claim 2,
wherein the isocoumarin derivative has the formula:
5
wherein R1 is C1-3 alkyl and R2 and R3 each represents hydrogen or C1-6 alkyl and n is 0 or 1.

### Claim 3 (depends on 1)

The method of claim 1,
wherein the tumor cell is contacted with the isocoumarin derivative and a chemotherapeutic agent selected from a Tubulin interactive or a DNA-interactive agent or an antimetabolite.

### Claim 4 (depends on 3)

The method of claim 3,
wherein the chemotherapeutic agent is a Tubulin interactive agent.

### Claim 5 (depends on 4)

The method of claim 4,
wherein the Tubulin interactive agent is a Paclitaxel.

### Claim 6 (depends on 3)

The method of claim 3,
wherein the chemotherapeutic agent is a DNA-interactive agent.

### Claim 7 (depends on 6)

The method of claim 6,
wherein the DNA-interactive agent is cyclophosphamide.

### Claim 8 (depends on 3)

The method of claim 3,
wherein the chemotherapeutic agent is an antimetabolite.

### Claim 9 (depends on 8)

The method of claim 8,
wherein the antimetabolite is 5-fluorouracil.

### Claim 10 (depends on 1)

A method for treating cancer in a human patient comprising administering an isocoumarin derivative of the formula given in claim 1 to said human patient and administering a chemotherapeutic agent as a second treatment modality, wherein said cancer is sensitive to the administration of said isocoumarin derivative when combined with the second treatment modality, and wherein such administration effects an enhanced treatment of said cancer relative to either said isocoumarin derivative or said shemotheraputic agent as a single modality.

### Claim 11 (depends on 1, 10)

The method of claim 10,
wherein the isocoumarin derivative comprises a compound of the formula given in claim 1, wherein X1, X2 and X3 each are oxygen; X4 is oxygen or sulfur, R1 is C1-3 alkyl; and R2 and R3 are each dependently selected from hydrogen and C1-6 alkyl.

### Claim 12 (depends on 11)

The method of claim 11,
wherein the isocoumarin derivative has the formula:
6
wherein R1 is C1-3 alkyl and R2 and R3 each represents hydrogen or C1-6 alkyl and n is 0 or 1.

### Claim 13 (depends on 10)

The method of claim 10,
wherein the chemotherapeutic agent is selected from a Tubulin interactive agent, a DNA-interactive agent, and an antimetabolite.

### Claim 14 (depends on 13)

The method of claim 13,
wherein the chemotherapeutic agent is a Tubulin interactive agent.

### Claim 15 (depends on 14)

The method of claim 14,
wherein the Tubulin interactive agent is a Paclitaxel.

### Claim 16 (depends on 10)

The method of claim 10,
wherein the chemotherapeutic agent is a DNA-interactive agent.

### Claim 17 (depends on 16)

The method of claim 16,
wherein the DNA-interactive agent is cyclophosphamide.

### Claim 18 (depends on 10)

The method of claim 10,
wherein the chemotherapeutic agent is an antimetabolite.

### Claim 19 (depends on 18)

The method of claim 18,
wherein the antimetabolite is 5-fluorouracil.

### Claim at position 20 (depends on 10)

20 The method of claim 10, wherein said tumor is selected from the group consisting of skin cancer, prostate cancer, lung cancer, brain cancer cell, breast cancer, ovarian cancer, cervical cancer, liver cancer, pancreatic cancer, colon cancer, stomach cancer and leukemia.
